Motor fluctuations—characterized by debilitating “on-off” phenomena in Parkinson’s disease management—continue to challenge clinicians. However, a randomized study demonstrated that continuous subcutaneous ND0612 infusion reduced OFF time by a least squares mean of 2.0 hours (95% CI: –3.3, –0.7; p = 0.003) compared to baseline, with the 24-hour infusion group experiencing a reduction of 2.8 hours (95% CI: –4.6, –0.9; p = 0.004).
As a Parkinson's disease treatment, ND0612 infusion delivers levodopa through a portable pump, providing continuous subcutaneous infusion that maintains more consistent plasma levels than oral dosing schedules. This approach addresses motor fluctuations Parkinson's patients often experience when intermittent oral doses fail to replicate physiological dopaminergic stimulation.
Earlier findings confirm that ND0612's safety profile aligns with traditional oral therapies, with serious adverse events reported in 3.1% of patients receiving ND0612 compared to none in the oral levodopa-carbidopa group during the double-blind phase of a phase 3 trial, affirming its role in long-term management.
ND0612 infusion aids in managing motor fluctuations by ensuring a stable dopaminergic environment, mitigating the peaks and troughs that underlie symptom variability. By smoothing levodopa delivery, this Parkinson's subcutaneous therapy option enhances “on” time and reduces off periods, translating into improved motor function and quality of life.
Patient selection for ND0612 should focus on those with motor fluctuations that remain refractory to optimized oral regimens, as recommended by the Movement Disorder Society's guidelines on continuous dopaminergic delivery methods.
ND0612 infusion offers a continuous subcutaneous delivery of levodopa-carbidopa, providing an alternative strategy for managing motor fluctuations in Parkinson's disease.
Key Takeaways:- Continuous subcutaneous ND0612 infusion offers improved management of motor fluctuations in Parkinson’s disease compared to oral therapies.
- ND0612's safety profile is comparable to traditional oral treatments.
- Patients not adequately managed by oral medications may find significant benefits from ND0612's stable dopaminergic regulation.